An OBGYN and skilled minimally invasive surgeon provides commentary on study: Shi et al. The associations between prenatal cannabis use disorder and neonatal outcomes. Addiction. 2021;10.1111/add.15467.
Pharmacist discusses important concerns regarding the accuracy of statements and findings from a systemic review on the efficacy and safety of cannabidiol in the treatment of anxiety: Skelley JW, et al. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003). 2020;60(1):253-261.
A molecular and cell biologist who works in the cannabis regulatory environment provides commentary on a recent study: Lambros AM, et al. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure. Sci Rep. 2023;13(1):5869. doi:10.1038/s41598-023-32671-9.
Board-certified gastroenterologist and hepatologist discusses findings from a review by Kienzl et al.: Cannabinoids and opioids in the treatment of inflammatory bowel diseases.
Pain researcher discusses findings from his latest study: Boehnke KF, et al. Qualifying conditions of medical cannabis license holders in the United States. Health Aff (Millwood). 2019;38(2):295-302.
A pediatric critical care physician provides commentary on a recent study: Efron D, et al. Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site I/II randomized placebo-controlled trial. BMJ Open. 2020;10(3):e034362.
Prolific inventor and chemist offers a historical perspective on the isolation of cannabinoids.
In light of recent policy changes, a Canadian researcher discusses findings from her study: Capler R, et al. Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. Int J Drug Policy. 2017;47:1-8.
Pain researcher discusses findings from his latest study: Boehnke KF, et al. Pills to Pot: Observational Analyses of Cannabis Substitution Among Medical Cannabis Users With Chronic Pain. J Pain. 2019;20(7):830-841.
As the silver tsunami approaches and palliative care experts prepare for the rise in older patients, cannabis is poised to play a larger role in end-of-life care. With a growing number of states recently enacting medical marijuana and adult-use cannabis legislation, many patients entering palliative care may already be using cannabis or may request use of cannabis for symptom management.